Zhongda Hospital: Carcinoma, Hepatocellular trials

The registry lists 28 Carcinoma, Hepatocellular studies with Zhongda Hospital as lead sponsor. 14 are open to participants now and 0 have results posted.

Phase 1 2Phase 2 4Phase 3 2No phase 23(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• TACE in Combination With Tislelizumab and Lenvatinib for Advanced HCC (CHANCE2602)Not yet recruitingNCT07836309
• A Multicenter Prospective Study on the Performance of Spectral CT for Evaluating Treatment Response After TACE in Hepatocellular CarcinomaRecruitingNCT07351669
• EDN Combined With TACE/HAIC and Second-Line Immune-Targeted Treatment Versus TACE/HAIC Alone in Locally Advanced HCC With Portal Vein Tumor Thrombosis After First-Line Therapy Failure: A Prospective, Multicenter, Randomized Controlled TrialNot yet recruitingNCT07187284Phase 1/2
• SIRT Versus cTACE for Unresectable HCC (CHANCE2506)RecruitingNCT06909708Not applicable
• Regional Lymph Node Metastasis and Survival Outcomes in Advanced HCCRecruitingNCT06876753
• Intravascular Radiofrequency Ablation of Sympathetic Nerves for the Treatment of Hepatocellular CarcinomaRecruitingNCT06694636Not applicable
• TACE Combined With ICIs Plus MTT After 125I Irradiation Stent Placement in HCC With Main PVTT.RecruitingNCT06669377
• Prognosis Stratification for Advanced HCC Receiving TACE with PD-1/PD-L1 Inhibitors and Molecular Target TherapiesRecruitingNCT06607120
• TACE With Thermosensitive Nanogel Versus Embosphere for HCCRecruitingNCT06593964Not applicable
• DEB-TACE With Visualable Microspheres Versus PVA Microspheres for HCCRecruitingNCT06190665Not applicable
• Efficacy, Safety, and Treatment Patterns of Transcatheter Arterial Chemoembolization (TACE) Combined With Atezolizumab and Bevacizumab in Unresectable Hepatocellular Carcinoma: a Multicenter, Retrospective, Observational Real-world StudyNot yet recruitingNCT06024252
• Yttrium-90 Carbon Microspheres in Patients With Unresectable Hepatocellular CarcinomaRecruitingNCT05957640Phase 1
• CT-based HVPG Assessment for Predicting the Prognosis of HCC With TACE (CHANCE-CHESS 2302)RecruitingNCT05704192
• Impact of Clinical Evident Portal Hypertension on HCC With TACE (CHANCE-CHESS 2301)RecruitingNCT05703750
• Development and Prospective Validation of a Heterogeneous Treatment Effect-Based Decision Model for Transarterial Chemoembolization Combined With or Without Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular CarcinomaCompletedNCT07109336Not applicable
• A Generative Model-based System for Predicting Survival and Guiding Treatment Decisions in Patients With Unresectable Hepatocellularcarcinoma Undergoing Transcatheter Arterial Chemoembolization in Combination With Immunotherapy and Targeted TherapyActive, not recruitingNCT07065786
• Immune Checkpoint Inhibitors and Anti-vascular Endothelial Growth Factor Antibody/Tyrosine Kinase Inhibitors With or Without TACE for Advanced HCC With Vascular InvasionsCompletedNCT06881446
• Immune Checkpoint Inhibitors and Anti-vascular Endothelial Growth Factor Antibody/Tyrosine Kinase Inhibitors With or Without HAIC for Unresectable HCC With Portal Vein Tumor ThrombosisCompletedNCT06881433
• Lipiodol-TACE With Idarubicin Based On a Specific Emulsion Ratio for Hepatocellular CarcinomaStatus unknownNCT05631613
• A Real World Study of Regogfinib in HCCStatus unknownNCT05557656
• TACE Combined With Penpulimab and Anlotinib for Advanced HCCStatus unknownNCT05344924Phase 2/3
• TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Advanced HCCCompletedNCT05332821
• TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Intermediate HCCCompletedNCT05332496
• Lipiodol-TACE With Idarubicin for Hepatocellular CarcinomaStatus unknownNCT05280444Phase 2/3
• Assessing the Prognosis of TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for HCC by Using Clinical and Imaging BiomarkersStatus unknownNCT05278195
• Efficacy and Safety of TACE in Combination With ICIs for HCC: a Real-world StudyCompletedNCT04975932
• Tislelizumab in Combination With TACE in Advanced Hepatocellular CarcinomaStatus unknownNCT04652492Phase 2
• Irradiation Stent Placement Plus TACE for HCC and PVTTStatus unknownNCT03730675Not applicable